[EN] DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS<br/>[FR] DÉRIVÉS DE TRIAZOLOPYRIDAZINES 6-SUBSTITUÉES EN TANT QU'AGONISTES DE REV-ERB
申请人:GENFIT
公开号:WO2013045519A1
公开(公告)日:2013-04-04
The present invention provides novel 6-substituted [1,2,4]triazolo[4,3-b]pyridazines that are agonists of Rev-Erb. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the activation of Rev-Erb has therapeutic effects, for instance in inflammatory and circadian rhythm-related disorders or cardiometabolic diseases.
[EN] INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS<br/>[FR] INHIBITEURS DE LA VOIE DE SIGNALISATION NOTCH ET LEUR UTILISATION DANS LE TRAITEMENT DE CANCERS
申请人:CELLESTIA BIOTECH AG
公开号:WO2020208139A1
公开(公告)日:2020-10-15
The present invention relates to new inhibitors of Notch signalling pathway and its use in the treatment and/or prevention of cancers.
本发明涉及新的Notch信号通路抑制剂及其在治疗和/或预防癌症中的应用。
Tuning the Reactivity of Peroxo Anhydrides for Aromatic C–H Bond Oxidation
作者:Afsaneh Pilevar、Abolfazl Hosseini、Marina Šekutor、Heike Hausmann、Jonathan Becker、Kevin Turke、Peter R. Schreiner
DOI:10.1021/acs.joc.8b01392
日期:2018.9.7
demanding cyclic peroxide (spiro[bicyclo[2.2.1]heptane-2,4′-[1,2]dioxolane]-3′,5′-dione, P4) for the direct hydroxylation of aromatic substrates. The new peroxide benefits from high thermal stability and can be synthesized from readily available starting materials. The aromatic C–H oxidation using P4 exhibits generally good yields (up to 96%) and appreciable regioselectivities.
Synthesis of 2,2′-biphenols through direct C(sp<sup>2</sup>)–H hydroxylation of [1,1′-biphenyl]-2-ols
作者:Shitao Duan、Yuanshuang Xu、Xinying Zhang、Xuesen Fan
DOI:10.1039/c6cc04756d
日期:——
A novel synthesis of diversely substituted 2,2′-biphenols through Pd(ii)-catalyzed,tBuOOH-oxidized, and hydroxyl-directed C(sp2)–H hydroxylation of [1,1′-biphenyl]-2-ols has been developed.
DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS
申请人:GENFIT
公开号:US20150038503A1
公开(公告)日:2015-02-05
The present invention provides novel 6-substituted [1,2,4]triazolo[4,3-b]pyridazines that are agonists of Rev-Erb. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the activation of Rev-Erb has therapeutic effects, for instance in inflammatory and circadian rhythm-related disorders or cardiometabolic diseases.